Cardiol Therapeutics (CRDL) investor relations material

Study Overview and Objectives

• ARCHER was a phase II, multi-center, randomized, double-blind, placebo-controlled trial evaluating Cardiol Rx in acute myocarditis, enrolling 109 patients across 34 centers globally, with an average age of 39 and predominantly male participants.

• The study focused on cardiac MRI endpoints predictive of prognosis, including extracellular volume (ECV), intracellular volume (ICV), left ventricular (LV) mass, and functional and volumetric cardiac parameters.

• Most patients had preserved LV function at baseline, presented with chest pain and elevated troponin, and were hospitalized for acute myocarditis.

• Cardiol Rx is a high-concentration cannabidiol oral solution targeting inflammasome activation, with a next-generation subcutaneous formulation (CRD38) in development for chronic heart conditions.

• The trial was designed and overseen by an international steering committee of myocarditis and heart failure experts, and results were presented at the European Society of Cardiology Working Group meeting.

Key Results and Clinical Insights

• Cardiol Rx led to a notable reduction in ECV (3.7 ml), ICV (5.6 ml), and LV mass (over 9 grams), indicating decreased myocardial inflammation and edema, with improvements in cardiac structure and chamber volumes.

• The magnitude of LV mass reduction is comparable to effects seen with established therapies for heart failure and hypertension.

• Cardiol Rx was safe and well tolerated, with balanced adverse event rates and no new safety signals identified.

• The findings provide clinical proof of concept for Cardiol Rx in treating inflammation-driven cardiac damage and support further development of CRD38.

• Chronic inflammation is a key driver of adverse cardiac remodeling, and Cardiol Rx directly targets this biology.

Expert Perspectives and Future Directions

• Experts highlighted ARCHER as the first study to show structural cardiac improvement with a therapeutic intervention in myocarditis.

• The reduction in LV mass supports the hypothesis that targeted therapy can remodel the heart by addressing inflammation and edema early in myocarditis.

• There is enthusiasm for expanding research into more severe myocarditis, heart failure with preserved ejection fraction, and checkpoint inhibitor myocarditis.

• The results strengthen confidence in the ongoing phase III MAVERICK trial in recurrent pericarditis and support broader development in inflammatory heart disease.

• The company is accelerating IND-enabling work for CRD38 and exploring partnerships for broader heart failure indications.